Pulmonary Drug Delivery Systems Market: By Product Type, By Technology, By Disease Indication, Pulmonary Arterial Hypertension, Others), By Distribution Channel, and Region Forecast 2019-2030
Pulmonary Drug Delivery Systems Market size was valued at US$ 53,120.16 million in 2023. It is expected to reach a value of US$ 78,156.36 million by 2030, growing at a CAGR of 6.1% from 2024-2030. Pulmonary drug delivery systems help to treat diseases such as asthma, and cystic fibrosis. The pulmonary route is used in the treatment of various respiratory disorders. Pulmonary drug delivery is gaining popularity owing to its target specificity. T
he pulmonary drug delivery system delivers the medication through the respiratory tract. It is majorly used in the treatment of conditions such as delivery of locally acting drugs directly to the sites of action. In December 2017, Sunovion receives the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution, also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behavior and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. Pulmonary Drug Delivery Systems Market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.
Study Period
2024-2030Base Year
2023CAGR
6.1%Largest Market
North AmericaFastest Growing Market
Asia Pacific
Increase in the prevalence of various chronic disease such as chronic pulmonary disease, tuberculosis, and bronchitis are expected to fuel the growth of pulmonary drug delivery systems market. The preference of the non-invasive techniques are witnessing to the growth of market. The minimum dosage requirement is another factor, which creates demand for the market. The technological advancements, growing support from the government and non-government organizations, increasing awareness and rising funds are expected to anticipate the growth of the market. However, the government regulatory issues in the approval of the product would hamper the growth of the market.
Geographically, market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America market is anticipated to expand at robust growth rates due to increase in prevalence of respiratory disorders. The surge in awareness about the modern treatment options and its adoption is expected to create healthy growth opportunities over the forecast period. As per World Health Organization (WHO) statistics, smoking is estimated to cause 71% of the lung cancer deaths and 42% of the chronic respiratory diseases worldwide. Out of the six regions of WHO, Europe was accounted for highest prevalence for smoking i.e., 29 per cent in 2008. The Europe market is expected to show a significant growth over the forecasted period. The Asia Pacific market is predicted to show tremendous growth in the emerging countries such as India and China owing to rising population coupled with increasing prevalence of respiratory disorders.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 53,120.16 million |
|
Market Size in 2030 |
US$ 78,156.36 million |
|
Market CAGR |
6.1% |
|
By Product Type |
|
|
By Technology |
|
|
By Disease Indication |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Pulmonary drug delivery systems market size was valued at US$ 53,120.16 Mn in 2023 and expected to reach a value of US$ 78,156.36 Mn by 2030 at a CAGR of 6.1%
The market key players are: Sunovion Pharmaceuticals Inc. (U.S) AstraZeneca plc (U.K) Omron Corporation (Japan) Novartis AG (Switzerland) Teva Pharmaceutical Industries Ltd. (Israel) GlaxoSmithKline (U.K) 3M (U.S) Boehringer Ingelheim GmbH (Germany)
The pulmonary drug delivery systems market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Pulmonary Drug Delivery Systems Market Introduction |
| 2.1.Global Pulmonary Drug Delivery Systems Market - Taxonomy |
| 2.2.Global Pulmonary Drug Delivery Systems Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Technology |
| 2.2.3.Disease Indication |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3. Global Pulmonary Drug Delivery Systems Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Pulmonary Drug Delivery Systems Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Pulmonary Drug Delivery Systems Market By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Metered Dose Inhaler |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Nebulizer |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Dry Powder Inhaler |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Pulmonary Drug Delivery Systems Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Manually Operated Inhalers |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Digitally Operated Inhalers |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Pulmonary Drug Delivery Systems Market By Disease Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Asthma |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Chronic Obstructive Pulmonary Disease (COPD) |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Pulmonary Arterial Hypertension |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Pulmonary Drug Delivery Systems Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Global Pulmonary Drug Delivery Systems Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. North America Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Metered Dose Inhaler |
| 10.1.2.Nebulizer |
| 10.1.3.Dry Powder Inhaler |
| 10.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Manually Operated Inhalers |
| 10.2.2.Digitally Operated Inhalers |
| 10.3. Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Asthma |
| 10.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
| 10.3.3.Pulmonary Arterial Hypertension |
| 10.3.4.Others |
| 10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11. Europe Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Metered Dose Inhaler |
| 11.1.2.Nebulizer |
| 11.1.3.Dry Powder Inhaler |
| 11.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Manually Operated Inhalers |
| 11.2.2.Digitally Operated Inhalers |
| 11.3. Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Asthma |
| 11.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
| 11.3.3.Pulmonary Arterial Hypertension |
| 11.3.4.Others |
| 11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12. Asia Pacific (APAC) Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Metered Dose Inhaler |
| 12.1.2.Nebulizer |
| 12.1.3.Dry Powder Inhaler |
| 12.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Manually Operated Inhalers |
| 12.2.2.Digitally Operated Inhalers |
| 12.3. Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Asthma |
| 12.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
| 12.3.3.Pulmonary Arterial Hypertension |
| 12.3.4.Others |
| 12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13. Middle East and Africa (MEA) Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Metered Dose Inhaler |
| 13.1.2.Nebulizer |
| 13.1.3.Dry Powder Inhaler |
| 13.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Manually Operated Inhalers |
| 13.2.2.Digitally Operated Inhalers |
| 13.3. Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Asthma |
| 13.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
| 13.3.3.Pulmonary Arterial Hypertension |
| 13.3.4.Others |
| 13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14. Latin America Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Metered Dose Inhaler |
| 14.1.2.Nebulizer |
| 14.1.3.Dry Powder Inhaler |
| 14.2. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Manually Operated Inhalers |
| 14.2.2.Digitally Operated Inhalers |
| 14.3. Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Asthma |
| 14.3.2.Chronic Obstructive Pulmonary Disease (COPD) |
| 14.3.3.Pulmonary Arterial Hypertension |
| 14.3.4.Others |
| 14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Sunovion Pharmaceuticals Inc. (U.S) |
| 15.2.2.AstraZeneca plc (U.K) |
| 15.2.3.Omron Corporation (Japan) |
| 15.2.4.Novartis AG (Switzerland) |
| 15.2.5.Teva Pharmaceutical Industries Ltd. (Israel) |
| 15.2.6.GlaxoSmithKline (U.K) |
| 15.2.7.3M (U.S) |
| 15.2.8.Boehringer Ingelheim GmbH (Germany) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
